2021
DOI: 10.1096/fasebj.2021.35.s1.03168
|View full text |Cite
|
Sign up to set email alerts
|

Effects of the putative antidepressant psilocin on the lipid‐raft proteome and lipid‐raft signaling

Abstract: Serotonergic hallucinogens psilocybin, and its active metabolite psilocin, have shown promise as rapid‐acting antidepressants. The FDA granted breakthrough therapy designation for psilocybin's use as an antidepressant in 2019, and phase II clinical trials are currently ongoing. Psilocybin is converted to psilocin following oral administration, and this metabolite is the primary active compound found in the central nervous system. As such, it is critically important to understand the cellular and molecular proc… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles